DelveInsight’s “Periodontal Disease Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Periodontal Disease pipeline landscapes. It comprises Periodontal Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Periodontal Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Periodontal Disease pipeline products.
Some of the key takeaways of the Periodontal Disease Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Noveome Biotherapeutics, Amyndas Pharmaceuticals, Cortexyme, etc., are developing therapies for the treatment of Periodontal Disease.
-
Emerging therapies such as ST266, AMY 101, Atuzaginstat, are expected to have a significant impact on the Periodontal Disease market in the coming years.
-
Amyndas Pharmaceuticals has planned for FDA end-of-phase II type B meeting and preparation for pivotal phase III study which has been planned, according to the company’s pipeline.
Get an overview of pipeline landscape @ Periodontal Disease Clinical Trials Analysis
Periodontal diseases are especially the result of infections and infections of the gums and bones that surround and help the teeth. In its early level, referred to as gingivitis, the gums can turn out to be swollen and purple, and they will bleed. In its greater severe form, referred to as periodontitis, the gums can pull away from the enamel, bone can be lost, and the tooth may loosen or maybe fall out.
Periodontal Disease Emerging Drugs
-
ST266 by Noveome Biotherapeutics,
-
AMY 101 by Amyndas Pharmaceuticals,
-
Atuzaginstat by Cortexyme
-
And others.
Scope of Periodontal Disease Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Noveome Biotherapeutics, Amyndas Pharmaceuticals, Cortexyme, and others.
-
Pipeline Therapies: ST266, AMY 101, Atuzaginstat,and others.
Table of Contents
|
1 |
Periodontal Disease Report Introduction |
|
2 |
Periodontal Disease Executive Summary |
|
3 |
Periodontal Disease Overview |
|
4 |
Periodontal Disease- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Periodontal Disease Pipeline Therapeutics |
|
6 |
Periodontal Disease Late Stage Products (Phase II/III) |
|
7 |
Periodontal Disease Mid Stage Products (Phase II) |
|
8 |
Periodontal Disease Early Stage Products (Phase I) |
|
9 |
Periodontal Disease Preclinical Stage Products |
|
10 |
Periodontal Disease Therapeutics Assessment |
|
11 |
Periodontal Disease Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Periodontal Disease Key Companies |
|
14 |
Periodontal Disease Key Products |
|
15 |
Periodontal Disease Unmet Needs |
|
16 |
Periodontal Disease Market Drivers and Barriers |
|
17 |
Periodontal Disease Future Perspectives and Conclusion |
|
18 |
Periodontal Disease Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @Periodontal Disease Drugs Pipeline Report
Related Reports:
DelveInsight’s Periodontal Disease – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Periodontal Disease, historical and forecasted epidemiology as well as the Periodontal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/